EcoDrugPlus

Chemokine (C-X-C Motif), Receptor 4b

Ensembl ID : ENSATEG00000002835
Gene Symbol: CXCR4B
2 Cross references
216 Possible Orthologues:

Cholecystokinin A Receptor

Ensembl ID : ENSATEG00000000609
Gene Symbol: CCKAR
4 Cross references
201 Possible Orthologues:

Cholecystokinin B Receptor A

Ensembl ID : ENSATEG00000005530
Gene Symbol: CCKBRA
3 Cross references
198 Possible Orthologues:

Cholesterol 24-Hydroxylase

Ensembl ID : ENSATEG00000017653
Gene Symbol: LOC113149355
3 Cross references
259 Possible Orthologues:

Cholesteryl Ester Transfer Protein, Plasma

Ensembl ID : ENSATEG00000008063
Gene Symbol: CETP
3 Cross references
151 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSATEG00000008868
Gene Symbol: CHRM3
3 Cross references
188 Possible Orthologues:

Cholinergic Receptor Muscarinic 4

Ensembl ID : ENSATEG00000012653
Gene Symbol: CHRM4
1 Cross references
186 Possible Orthologues:

Cholinergic Receptor Muscarinic 5

Ensembl ID : ENSATEG00000003262
Gene Symbol: CHRM5
3 Cross references
195 Possible Orthologues:

Cholinergic Receptor, Muscarinic 2a

Ensembl ID : ENSATEG00000027927
Gene Symbol: CHRM2A
1 Cross references
196 Possible Orthologues:

Cholinergic Receptor, Muscarinic 5b

Ensembl ID : ENSATEG00000021684
Gene Symbol: CHRM5B
3 Cross references
190 Possible Orthologues:

Cholinergic Receptor, Nicotinic, Beta 2

Ensembl ID : ENSATEG00000023770
Gene Symbol: CHRNB2
2 Cross references
198 Possible Orthologues:

Coagulation Factor Ii (Thrombin) Receptor

Ensembl ID : ENSATEG00000004415
Gene Symbol: F2R
3 Cross references
211 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).